Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia including social, psychological, physical and recreational aspects of daily living



Data highlight for...

Related Keywords

Nevada ,United States ,Michigan ,Richard Jackson ,Las Vegas ,Eric Hughes ,Drug Administration ,Abnormal Involuntary Movement Scale ,National Alliance On Mental Illness ,Psych Congress Elevate Annual Meeting ,Teva Pharmaceutical Industries Ltd ,Teva Pharmaceuticals ,Psych Congress Elevate ,Teva Pharmaceutical Industries ,Congress Elevate Annual Meeting ,Executive Vice President ,Chief Medical Officer ,Clinical Global Impression ,Reported Outcome ,Assistant Clinical Adjunct Professor ,Michigan School ,Tardive Dyskinesia ,Release Tablets ,Adverse Events ,Malignant Syndrome ,Melanin Containing Tissues ,Adverse Reactions ,Prescribing Information ,Pharmaceutical Industries ,Private Securities Litigation Reform Act ,Quarterly Report ,Annual Report ,Nova Science ,From Phenomenology ,Mental Illness ,